Abstract Purpose: The dismal outcome of esophageal cancer patients highlights the need for novel prognostic biomarkers, such as microRNAs (miRNA). Although recent studies have established the role of miRNAs in esophageal carcinoma, a comprehensive multicenter study investigating different histologic types, including squamous cell carcinoma (SCC) and adenocarcinoma with or without Barrett's, is still lacking. Experimental Design: miRNA expression was measured in cancerous and adjacent noncancerous tissue pairs collected from 100 adenocarcinoma and 70 SCC patients enrolled at four clinical centers from the United States, Canada, and Japan. Microarray-based expression was measured in a subset of samples in two cohorts and was validated in all available samples. Results: In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue. In SCC patients, we found elevated miR-21 and reduced miR-375 expression levels in cancerous compared with noncancerous tissue. When comparing cancerous tissue expression between adenocarcinoma and SCC patients, miR-194 and miR-375 were elevated in adenocarcinoma patients. Significantly, elevated miR-21 expression in noncancerous tissue of SCC patients and reduced levels of miR-375 in cancerous tissue of adenocarcinoma patients with Barrett's were strongly associated with worse prognosis. Associations with prognosis were independent of tumor stage or nodal status, cohort type, and chemoradiation therapy. Conclusions: Our multicenter-based results highlight miRNAs involved in major histologic types of esophageal carcinoma and uncover significant associations with prognosis. Elucidating miRNAs relevant to esophageal carcinogenesis is potentially clinically useful for developing prognostic biomarkers and identifying novel drug targets and therapies.
Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer deaths worldwide (1) . Often diagnosed at later stages, the survival rate for affected patients is very low, ranging from 10% in Europe (2) to 16% in the United States (3). The incidence of esophageal cancer varies greatly by geographic location, where it is most common in China, southeast Africa, and Japan, and by gender, where males are affected more than females (7:1 ratio). In recent years, the incidence of Barrett's-associated adenocarcinoma, mainly caused by gastric reflux and obesity, has been rising, whereas the incidence of squamous cell carcinoma (SCC), mainly caused by cigarette smoking and alcohol consumption, has been decreasing in the United States (4). Barrett's results from chronic gastric reflux and is characterized by the replacement of normal esophageal squamous cell epithelium by metaplastic columnar epithelium. This chronic inflammatory condition is a well-recognized precursor of esophageal adenocarcinoma (5) .
MicroRNA (miRNA) are small (20-24 nucleotides), wellconserved, noncoding RNA molecules that regulate the translation of mRNAs (6) . Since the discovery of the first miRNA, lin-4, in Caenorhabditis elegans in 1993 (7), the miRNA registry has housed sequences from 218 miRNAs in 2002 to 9,539 as of March 2009, including miRNAs in primates, rodents, birds, fish, worms, flies, plants, and viruses (8) . Each miRNA is thought to play a role in the post-transcriptional regulation of hundreds of genes, and translational blockade of a given gene may require binding of more than one miRNA (6) . The role of miRNAs has been well established in various human cancers (9) and altered miRNA expression has been reported in most tumor types (10, 11) . In addition, miRNAs are often located in fragile sites or cancer-associated genomic regions (12) . Recently, we and others reported the involvement of let-7 and miR-155 in lung cancer diagnosis and prognosis (13) (14) (15) and high expression of miR-21 was associated with poor survival and therapeutic outcome in colon cancer (16) . Other expression profiling studies identified miRNA signatures in hepatocellular carcinoma (17, 18) , pancreatic cancer (19) , breast cancer (20) , papillary thyroid cancer (21) , and chronic lymphocytic leukemia (22) . Importantly, the successful use of antagomirs to silence miRNAs in mice (23) and nonhuman primates (24) suggests the possible therapeutic use of miRNAs. In the context of esophageal carcinoma, increased expression of RNA-SEN, a miRNA processing enzyme, in tumor samples of SCC patients suggests the role of miRNA in esophageal tumor progression (25) . Recently, miRNA expression profiles unique to esophageal cancer histologic types, Barrett's status, and survival have been uncovered (26) (27) (28) , albeit limited samples sizes.
In this study, we used four independent clinical centers to confirm and find novel miRNAs involved in the pathogenesis of human esophageal cancers and Barrett's and to explore their utility as predictors of prognosis. Using 100 adenocarcinoma and 70 SCC patients split into training set (32 adenocarcinoma and 44 SCC) and validation set (68 adenocarcinoma and 26 SCC), we first generated miRNA microarray (29) profiles and confirmed expression differences of relevant miRNAs using real-time quantitative reverse transcription-PCR (qRT-PCR) in all samples. Furthermore, we analyzed associations between miRNA expression and survival to explore the possible utility of miRNAs as prognostic biomarkers of esophageal carcinoma.
Materials and Methods
Cohorts and clinicopathologic data. A total of 170 patients with available cancerous and adjacent noncancerous tissue from surgical resection were divided into training and validation sets. The training set includes 44 SCC cases and 32 adenocarcinoma cases, of which 18 were also diagnosed with Barrett's, whereas the validation set comprises 26 SCC cases and 68 adenocarcinoma cases, including 45 patients also diagnosed with Barrett's. Patients were recruited from four different cancer centers: (a) University of Maryland Medical System in Baltimore, Maryland; (b) Nippon Medical School in Tokyo, Japan; (c) New York PresbyterianWeill Cornell Medical Center in New York, New York; and (d) Queen Elizabeth II Health Science Centre in Halifax, Nova Scotia, Canada (Table 1) . Samples collected from the University of Maryland cohort were divided such that 32 adenocarcinoma and 11 SCC patients with sufficient RNA for microarray and qRT-PCR analysis were included in the training set, and 41 adenocarcinoma and 13 SCC were included in the validation set. Disease stage and survival were obtained from medical records, pathology reports, State of Maryland records, and the National Death Index. These studies were approved by the institutional review boards of the participating institutions. Clinicopathologic data relevant to this study were provided from their respective sources and include gender, age, histology, presence/absence of Barrett's, neoadjuvant chemoradiation therapy administration (before surgery), alcohol consumption, smoking status, and pathologic staging (Table 1) .
RNA isolation and quantification of miRNA. Total RNA used for quantification of miRNA levels was extracted from esophageal tissue using Trizol (Invitrogen) according to the manufacturer's procedures. miRNA expression levels were measured using miRNA microarray chips version 3 (Ohio State University) containing 329 human miRNAs and 249 mouse miRNA probes in duplicate (29) . Total RNA (5μg) was converted to biotin-labeled first-strand cDNA, hybridized onto the chips, and processed by direct detection of the biotin-containing transcripts by streptavidin-Alexa 647 conjugate. Slides were subsequently scanned with the Axon 4000B Scanner (Molecular Device) and spot intensities were quantified with Genepix (version Pro 6.0.1.00). Microarray data was submitted to the Gene Expression Omnibus (GSE13937).
Validation of miRNA altered levels was done by qRT-PCR using TaqMan miRNA reverse transcription assays (Applied Biosystems) and appropriate primers following the manufacturer's instructions. In brief, 10 ng total RNA was used as a template for a 15 μL reverse
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transcription reaction using probes specially designed for specific mature miRNAs. For each miRNA, reactions were done in triplicate using the 7500 RT-PCR system (Applied Biosystems) and RNU66 (Applied Biosystems) was used as a normalization control.
Statistical analysis. Preprocessing and normalization of miRNA microarray expression values were done in R (version 2.6.0), and differential expression analysis was carried out in BRB ArrayTools (version 3.5.0) developed by Dr. Richard Simon and Amy Peng Lam. 9 (see Supplementary Data for more detail). Differential expression analysis was restricted to human miRNA probes with nonmissing intensity values in at least 25% of the samples. Altered expression of miRNA probes was determined using the Class Comparison Tool, which performs t tests, and expression changes with P < 0.05 and corresponding false discovery rate <10% were considered to be statistically significant. A paired t test was done when comparing cancerous and adjacent noncancerous tissue expression, whereas a t test with a random block design by date was applied for all other comparisons.
qRT-PCR measurements were considered concordant with microarray expression when both measurements showed statistically significant and same direction fold changes. qRT-PCR expression counts were normalized to RNU66 counts and two-sided paired or unpaired t tests (for comparing cancerous and adjacent noncancerous tissue and all other comparisons, respectively) were done.
Survival analysis was done on dichotomized miRNA expression values using the median expression value within each cohort as a cutoff. Kaplan-Meier curves were constructed and survival differences were assessed using the log-rank test. The proportional hazards assumption was tested using Schoenfeld residuals and was met for all models reported. Univariate and multivariate Cox analysis was done to assess associations between clinical variables and prognosis and to adjust for relevant clinical variables (see Supplementary Data). Multivariate Cox models included cohort type to account for the different cohorts that were used in the study, staging or nodal involvement, and therapy as they were associated with survival in the univariate analysis.
To ensure a sufficient number of events per group in the multivariate analysis, samples from different cohorts were combined. To make sure that cohort type did not bias associations with prognosis, we verified that there was no association between cohort type and survival (see Supplementary Fig. S1 ). In addition, miRNA expression was dichotomized into high and low within each cohort using a median cutoff. Finally, all multivariate Cox models were also adjusted for cohort type to ensure independence of miRNA prognosis associations from cohort type associations. Of note, HRs showed the same trend in each cohort for a given miRNA, although, in some cases, P values exceeded 0.05 (data not shown).
Importantly, the administration or lack thereof of neoadjuvant chemoradiation therapy was not associated with survival. Statistical significance of expression validation and survival analysis was achieved when P < 0.005 (corresponding to P < 0.05 after applying the stringent Bonferroni correction for nine multiple comparisons) and borderline statistical significance was achieved when 0.005 < P < 0.05.
Sample classifications were done using the R package "pamr" (version 1.34.0), Prediction Analysis of Microarrays (30) . Robustness of the models was evaluated using bootstrap techniques. P values describing the accuracy level (an 80% accuracy significantly different from random) and the difference in accuracies observed between models built using all probes and models built after removing "persistent probes" were calculated (see Supplementary Data). Finally, we performed receiving operating curve analysis to select optimal model parameters (see Supplementary Data).
Results
Cancerous and adjacent noncancerous tissues resected from 170 patients were used in this study, which was conducted in three steps: (a) analysis of adenocarcinoma patients (n = 32 in training set and n = 68 in validation set), including Barrett's-associated and sporadic adenocarcinoma; (b) analysis of SCC patients (n = 44 in training set and n = 26 in validation set); and (c) comparison of adenocarcinoma and SCC patients. Clinical characteristics of all patients used in this study are summarized in Table 1 . In adenocarcinoma patients, patients in each cohort differed by administration of neoadjuvant chemoradiation therapy, alcohol consumption, and pathologic staging, whereas differences in gender, nodal status, and stage were observed between cohorts of SCC patients.
A flow chart of the analysis performed is shown in Fig. 1 . miRNA microarray expression values were first evaluated in training set samples (Supplementary Table S1 ) and expression of select miRNAs was subsequently confirmed using qRT-PCR in all samples. The predictive capacity of miRNAs was first evaluated by inputting microarray expression values in Prediction Analysis of Microarrays and classifying samples by tumor status and types (Supplementary Table S2 ). When classifying adenocarcinoma samples, 71% accuracy (P = 0.005) was obtained when discerning cancerous from adjacent noncancerous tissue. Diagnostic prediction of adenocarcinoma patients with Barrett's increased the accuracy to 77% (P = 0.006), whereas the prediction of patients with sporadic adenocarcinoma yielded near random class assignment (58% accuracy). Analogously, there were no differentially expressed miRNAs identified in patients with sporadic adenocarcinoma using standard t tests. Furthermore, 78% accuracy (P = 0.003) was obtained when classifying cancerous tissue expression of Barrett's-associated or sporadic adenocarcinoma patients. Noncancerous tissue expression was not predictive of Barrett's-associated adenocarcinoma. Classification of SCC samples into cancerous and noncancerous tissue yielded 86% accuracy (P < 1e-4). Finally, classification of samples by histology yielded 82% and 85% accuracies using cancerous and noncancerous tissue expression profiles, respectively. Importantly, there is a large overlap between miRNA probes that contribute most to the classifications (Supplementary Table S3 ) and those that show differential expression using ANOVA. These miRNAs are of interest as they may play a role in esophageal carcinogenesis.
miRNA differential expression in adenocarcinoma patients. Alterations in miRNA microarray expression levels specific to adenocarcinoma patients were evaluated in 32 cancerous and adjacent noncancerous tissue pairs (Supplementary Tables S4 and S5) . Interestingly, many of the differentially expressed probes are located in fragile sites and cancer-associated genomic regions. Expression measurements of select miRNAs (P < 0.05, false discovery rate <10%, and largest fold changes) were validated using qRT-PCR. Elevated expression of miR-21, miR-223, miR-192, and miR-194 and reduced expression of miR-203 in adenocarcinoma cancerous compared with adjacent noncancerous tissue were confirmed in training and validation set samples, including those from the University of Maryland and Canada cohorts ( Fig. 2A) . These five miRNAs were also differentially expressed between adenocarcinoma patients with or without Barrett's. Of note, miR-21, miR-223, miR-192, and miR-194 were also differentially expressed in patients that have received neoadjuvant chemoradiation therapy compared with those that have not (Supplementary Table S6 ).
In addition, altered expression of miR-192 (Barrett's/ non-Barrett's fold change = 6.94; P = 0.0008) and miR-194 (Barrett's/non-Barrett's fold change = 5.78; P = 0.0009) in cancerous tissue between Barrett's-associated and sporadic adenocarcinoma patients was confirmed by qRT-PCR in all samples of the University of Maryland cohort. This association was not confirmed in the Canada cohort (miR-192: Barrett's/nonBarrett's fold change = 0.41; P = 0.17 and miR-194: Barrett's/ non-Barrett's fold change = 0.46; P = 0.22). Adenocarcinoma patients from the University of Maryland and Canada cohort differ by stage and neoadjuvant chemoradiation therapy (none of the Canada cohort patients have undergone therapy). Nonetheless, miR-192 and miR-194 were not differentially expressed between patients with low stage (tumor-node-metastasis 0 and I) and high stage (tumor-node-metastasis II-IV). Due to an insufficient number of University of Maryland cohort patients that have not undergone chemoradiation therapy and do not have Barrett's (n = 2), we were unable to assess whether the Barrett's-associated differential expression is affected by therapy. However, miR-192 and miR-194 expression is increased in Barrett's-associated patients that have undergone chemoradiation therapy. More detailed differential expression by cohort type of all miRNAs evaluated is detailed in Supplementary Table S7 .
Association between miRNA expression and survival of adenocarcinoma patients. miRNA expression values derived from qRT-PCR were dichotomized based on a within cohort median cutoff (see Materials and Methods Table S6 ). There was no significant association between miRNA and survival in adenocarcinoma patients without Barrett's. miRNA differential expression in SCC patients. Altered miRNA expression specific to SCC was first analyzed using microarrays in 44 patients (Supplementary Tables S1 and S9) . Thirty-five percent of the probes differentially expressed between cancerous and noncancerous tissue are located in cancer-associated genomic regions. Expression measurements of miRNAs with largest fold changes (P < 0.05, false discovery rate <10%) were confirmed using qRT-PCR in all available cases, including 26 additional validation set samples. Elevated expression levels of miR-21 and reduced levels of miR-375 were confirmed in patients from the University of Maryland, Japan, and Cornell cohorts when comparing cancerous and adjacent noncancerous tissue (Fig. 2B) . Neither miR-21 nor miR-375 expression was associated with administration of neoadjuvant chemoradiation therapy (Supplementary Table S6 ). Interestingly, elevated levels of miR-21 in cancerous tissue were also observed in adenocarcinoma samples, suggesting that it might participate in the different histologic types of esophageal tumorigenesis. Detailed differential expression results by cohort type are shown in Supplementary Table S7 .
Association between miRNA expression and survival in SCC patients. Similar to the analysis of adenocarcinoma patients, qRT-PCR expression values were dichotomized based on a median cutoff within each cohort. Kaplan-Meier analysis revealed a statistically significant association between high expression of miR-21 in noncancerous tissue (HR, 4.23; 95% CI, 1.68-10.61) and worse prognosis ( Fig. 3B ; Table 2; Supplementary  Table S8 ). Elevated levels of miR-155 (HR, 2.69; 95% CI, 1.12-6.46), miR-146b (HR, 2.4; 95% CI, 1.03-5.56), and miR-181b (HR, 2.76; 95% CI, 1.15-6.62) in noncancerous tissue showed a borderline significant association with worse prognosis. Furthermore, reduced miR-223 expression in cancerous tissue (HR, 0.43; 95% CI, 0.19-0.97) was borderline associated with poor prognosis. miR-21, miR-155, miR-146b, and miR-181b expression is not associated with neoadjuvant chemoradiation therapy in SCC patients (Supplementary  Table S6 ). Multivariate Cox modeling revealed that all associations between the expression of these miRNAs and survival are independent of cohort type, nodal involvement, and therapy.
miRNA differential expression between adenocarcinoma and SCC patients. Microarray analysis results are shown in Supplementary Table S10 and show that differential expression by histologic type is only detected in cancerous tissue, suggesting that adjacent noncancerous tissue in both histologic subtypes have similar miRNA profiles. Elevated expression levels in cancerous tissue of miR-194 (adenocarcinoma/SCC fold change = 4.59; P = 0.005) and miR-375 (adenocarcinoma/SCC fold change = 6.41; P = 0.009) in adenocarcinoma compared with SCC patients were observed using qRT-PCR in patients without Barrett's. qRT-PCR expression differences between adenocarcinoma and SCC patients was evaluated in the University of Maryland cohort only, because it is the only cohort that includes a sufficient amount of adenocarcinoma and SCC patients. In addition, only patients without Barrett's were evaluated to avoid confounding of differential expression by Barrett's status. Altered expression in these miRNAs underlies differences in biological mechanisms involved in the two different histologic types of esophageal cancerous cells.
Discussion
To our knowledge, we have performed the largest study to date that assesses the potential diagnostic and prognostic utility Fig. 3 . Kaplan-Meier analysis depicting associations with qRT-PCR miRNA expression and survival. miRNA expression values were dichotomized into low and high groups using the within cohort median expression value as a cutoff. A, associations observed in adenocarcinoma patients with and without Barrett's. Reduced expression of miR-375 in cancerous tissue of adenocarcinoma patients with Barrett's is associated with worse prognosis. This association is not observed in adenocarcinoma patients without Barrett's. B, associations observed in SCC patients. Elevated expression of miR-21 in noncancerous tissue is associated with worse prognosis. This association is not found when cancerous tissue expression is evaluated. Survival profiles were compared using the log-rank test.
of miRNAs in esophageal cancer. miRNA expression was evaluated in 170 cancerous and adjacent noncancerous tissue pairs and we identified miRNAs important for classification of samples into diagnostic and Barrett's categories. Elevated miR-21 levels were observed in both SCC and adenocarcinoma samples, indicating that miR-21 involvement in esophageal carcinogenesis is independent of histologic type. Furthermore, increased expression of miR-194, miR-192, and miR-223 and reduced expression of miR-203 are observed in adenocarcinoma patients from two independent clinical centers, whereas decreased expression of miR-375 is detected in SCC patients from three clinical centers. Altered expression of these miRNAs is specific to histologic type, which may provide clues as to the different molecular progression undertaken by these cancers and suggests a potential avenue for histology-specific therapy to improve prognosis.
Expression levels of miRNAs mentioned above were validated in samples from the testing and validation cohorts using qRT-PCR. Overexpression of miR-21 is of interest because it is ubiquitously induced in solid tumors, including esophagus, liver, lung, breast, stomach, prostate, colon, and pancreas (10, 11, 13, (16) (17) (18) (19) (20) (21) and in chronic lymphocytic leukemia (22) . miR-21 targets tumor and metastasis suppressor genes, including phosphatase and tensin homologue PTEN (31), tumor suppressor gene tropomyosin 1 TPM1 (32), programmed cell death 4 PDCD4 (33, 34) , and Sprouty2 (35) , thereby showing its involvement in tumor growth, invasion, and metastasis. Our laboratory has also revealed that elevated miR-21 in tumors are associated with poor prognosis and therapeutic outcome in colon cancer (16) .
Importantly, we show here that altered levels of miR-21 in noncancerous tissue of SCC patients are associated with survival, suggesting that miR-21 may have an effect in SCC tumors via the stroma. Knowing that inflammatory responses are implicated in all stages of tumorigenesis (36) , targeting miR-21 in stromal cells provides a possible avenue for chemoprevention. We have established previously that the combination of cytokine expression in noncancerous and cancerous tissue of lung adenocarcinoma patients is a predictor of survival, suggesting a possible interaction between the tumor and its surrounding lung environment (37) . A similar association between cytokine expression and survival was observed in esophageal cancer. 10 Furthermore, there is growing evidence for the role of miRNAs in regulating innate and acquired immune response (38) (39) (40) . Specifically, miR-21 expression has been associated with immune-related diseases, including B-cell lymphoma (41) and chronic lymphocytic leukemia (22) . Furthermore, a recent study showed the Stat3-dependent effect of interleukin-6 on miR-21 induction, which contributed to the oncogenic potential of Stat3 (42) . Consequently, our finding that increased levels of miR-21 are associated with worse prognosis in noncancerous tissue is possibly a reflection of an immune response that is associated with tumorigenesis.
In addition, our study shows that miR-375 levels in cancerous tissue are associated with prognosis in Barrett's-associated adenocarcinoma patients. A recent study has shown that miR-375-deficient mice are hyperglycemic and that the pancreatic α-cell mass is decreased, a sign of impaired proliferation (43) . Furthermore, the same group performed a combined analysis of putative targets and microarray expression showing that putative miR-375 targets control cellular growth and proliferation (43) . Experimentally validated targets of miR-375, as described in Tarbase (44) , include Mxi1, JAK2, and Ahr. MXi1 is a c-MYC antagonist found previously to be overexpressed in esophageal adenocarcinoma (45) . A direct association between JAK2 and phosphoinositide 3-kinase on glycine-extended gastrin stimulation has been shown in Barrett's-associated adenocarcinoma cells (46) . The suppression of Ahr signaling as a chemopreventive approach was supported by a study that showed a reduction of DNA adducts in esophageal SCC cell lines by blocking the transcription factor Ahr (47) . These results combined with our finding that reduced levels of miR-375 are associated with worse prognosis suggest that miR-375 may be a good marker for cell proliferation.
In concordance with our observations, a recent study based on a cohort of 7 patients reported that miR-21 is overexpressed in adenocarcinoma, miR-143 is underexpressed in adenocarcinoma, and miR-194 is overexpressed in Barrett's (28) . The study also reported overexpression of miR-203, miR-205, miR-143, and miR-215 in Barrett's. Another study reported the analysis of 20 cases and 9 normal epithelial tissue and revealed an overexpression of miR-21 and underexpression of miR-203 and miR-205 in cancerous tissue in both histologic subtypes (26) , which is concordant with our microarray results. In a previous study evaluating miRNA expression in SCC patients, high expression of miR-103 and miR-107 correlated with poor survival in 30 patients, a finding confirmed in an independent set of 22 SCC patients (27) . These results were not in concordance with our analysis perhaps due to their use of a different microarray platform and more limited sample size. The administration of neoadjuvant chemoradiation therapy (before surgery) in 54% of patients used in this study and complete pathologic response in 22% of patients limits our ability to negate the role of therapy on associations between miRNA expression and diagnosis/prognosis. Differential expression in cancerous and noncancerous tissues was observed in patients that had or had not undergone neoadjuvant chemoradiation therapy (Supplementary Table S10 ), although associations were not consistent across different cohort types. Because therapy was administered before tissue collection and no pretherapy tissue is available, it was not possible to directly predict therapeutic response. Of note, patients with complete pathologic response are not necessarily cured perhaps due to remaining systemic processes or the inability to detect small metastatic disease (48) . It is still a debate whether such patients have longer survival than patients without complete pathologic response (49) . This observation further shows the importance of identifying molecular biomarkers, such as miRNAs, that would help refine staging and predict treatment response. Furthermore, although chronic alcohol consumption and smoking may adversely affect survival of esophageal cancer patients (50), we were unable to adequately assess the influence of those covariates in our multivariate Cox analysis due to missing values (16% and 23% missing values for smoking and alcohol consumption, respectively). Although preliminary analysis of available data did not show an association between smoking, alcohol consumption, and survival (data not shown), further studies are warranted to confirm the association of miRNAs with survival independent of these two factors.
In conclusion, we identified miRNAs whose expression is altered in and between SCC and adenocarcinoma cancerous tissue and in cancerous tissue between Barrett's-associated and sporadic adenocarcinoma cancerous tissue. Furthermore, we have established a strong association between elevated miR-21 levels in the noncancerous tissue of SCC patients with worse prognosis, thereby suggesting a possible association between miR-21 in the stromal environment, immune response, and SCC. Prognostic association of miRNA expression in noncancerous tissue is of particular interest because altered levels of these miRNAs may be evident before advanced disease stage and the occurrence of symptoms. In Barrett's-associated adenocarcinoma patients, high levels of miR-375, which targets genes associated with tumor cell proliferation, in the cancerous tissue were associated with worse prognosis. The ability to block miRNA transcription may open avenues for the possible use of miRNAs in identifying novel drug targets and therapies for esophageal carcinoma.
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